News and Reports | December 2, 2025
The upcoming removal of Entresto, Stelara and Xarelto from the negotiation program appears to be consistent with the inflation Reduction Act’s procedure for dropping drugs once competition enters the market.
“The Medicare Negotiation Program was designed to serve as a check on the monopoly power of the pharmaceutical industry and the highest-cost and most commonly prescribed drugs that have evaded competition and have kept Americans paying between 4 and 8 times more than patients in other high-income countries. Increasing competition via generic or biosimilar rivals entering the market has historically lowered prices and should benefit patients,” Merith Basey, executive director of Patients for Affordable Drugs, told Inside Health Policy.